Experiences of persons with multiple sclerosis with the Covid-19 vaccination: A cross-sectional study of the Swiss Multiple Sclerosis Registry.

Stanikić, Mina; Twomey, Eric; Puhan, Milo A; Kamm, Christian P; Salmen, Anke; Ajdacic-Gross, Vladeta; Zecca, Chiara; Gobbi, Claudio; von Wyl, Viktor (2023). Experiences of persons with multiple sclerosis with the Covid-19 vaccination: A cross-sectional study of the Swiss Multiple Sclerosis Registry. Multiple sclerosis and related disorders, 74, p. 104707. Elsevier 10.1016/j.msard.2023.104707

[img]
Preview
Text
1-s2.0-S2211034823002110-main.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (881kB) | Preview

BACKGROUND

Despite strong recommendations for coronavirus disease 2019 (Covid-19) vaccination by multiple sclerosis (MS) organizations, some persons with MS (pwMS) remain vaccine hesitant. The Swiss MS Registry conducted a survey to explore Covid-19 vaccine hesitancy, self-reported side effects and changes in MS symptoms following vaccination in adult pwMS.

METHODS

Self-reported data were analyzed cross-sectionally. Multivariable logistic regression was used to explore participant characteristics associated with Covid-19 vaccine hesitancy.

RESULTS

Of 849 respondents, 73 (8.6%) were unvaccinated. Hesitation to vaccinate was most often a personal preference (N = 42, 57.53%). Factors negatively associated with vaccine hesitancy included older age (OR = 0.97 per year, 95% CI [0.94, 0.99]) and regularly seeing healthcare professionals (OR = 0.25, 95% CI [0.07, 0.85]). A history of confirmed Covid-19 infection (OR = 3.38, 95% CI [1.69, 6.77]) and being underweight (OR = 4.50, 95% CI [1.52, 13.36]) were positively associated with vaccine hesitancy. Of 768 participants who provided information, 320 (41.2%) and 351 (45.2%) reported vaccination side effects after the first and second vaccinations, respectively. Changes in MS symptoms were reported by 49 (6.3%) participants after the first and 67 (9.0%) participants after the second vaccination, and were most often described as increased or new-onset fatigue (N = 17/49 (34.7%) after the first and N = 21/67 (31.3%) after the second dose).

CONCLUSIONS

Covid-19 vaccine hesitancy was low among surveyed pwMS. The risk of vaccine hesitancy was higher among younger pwMS, those with a history of Covid-19 infection, and those without regular contact with healthcare professionals.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Kamm, Christian Philipp

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2211-0356

Publisher:

Elsevier

Language:

English

Submitter:

Pubmed Import

Date Deposited:

18 Apr 2023 11:26

Last Modified:

18 Jun 2023 00:15

Publisher DOI:

10.1016/j.msard.2023.104707

PubMed ID:

37068368

Uncontrolled Keywords:

Covid-19 Multiple sclerosis Side effects Vaccination Vaccine hesitancy

BORIS DOI:

10.48350/181815

URI:

https://boris.unibe.ch/id/eprint/181815

Actions (login required)

Edit item Edit item
Provide Feedback